NEXTBio Capital Management LP's Q1 2026 13F: 1 new position

Form 13F-HR for the quarter ended Mar 31, 2026 · filed May 14, 2026 · 24 reported positions · accession 0001172661-26-001957

What changed this quarter

NEXTBio Capital Management LP's changes in reported equity positions, Q1 2026
Activity Security Weight before Weight now Change Shares Shares %
Increased COMPASS PATHWAYS PLC (CMPS) 3.0% 5.2% +2.1 pts +1.27M sh +169%
Increased RHYTHM PHARMACEUTICALS INC (RYTM) 4.2% 5.1% +0.8 pts +58,492 sh +87%
Increased TERNS PHARMACEUTICALS INC (TERN) 13.1% 14.8% +1.7 pts +53,344 sh +10%
Increased ZENAS BIOPHARMA INC (ZBIO) 6.9% 3.9% −3.0 pts +105K sh +33%
Increased STRUCTURE THERAPEUTICS INC (GPCR) 3.9% 3.0% −0.9 pts +38,796 sh +41%
New SUMMIT THERAPEUTICS INC (SMMT) — 0.8% +0.8 pts +89,717 sh new
Reduced COMPASS THERAPEUTICS INC (CMPX) 3.5% 2.1% −1.4 pts −266K sh −24%
Increased COGENT BIOSCIENCES INC (COGT) 2.0% 2.3% +0.3 pts +35,369 sh +37%
Reduced ORIC PHARMACEUTICALS INC (ORIC) 3.0% 3.1% +0.1 pts −92,101 sh −15%
Reduced EVOMMUNE INC (EVMN) 2.3% 2.0% −0.3 pts −44,223 sh −19%
Increased DISC MEDICINE INC (IRON) 2.0% 1.6% −0.4 pts +9,877 sh +23%
Increased ZAI LAB LTD (ZLAB) 1.7% 1.6% −0.1 pts +20,000 sh +12%
Increased INVENTIVA SA (IVA) 3.5% 3.4% −0.1 pts +34,783 sh +3%
Reduced XENON PHARMACEUTICALS INC (XENE) 4.8% 4.9% +0.1 pts −479 sh 0%
Reduced VAXCYTE INC (PCVX) 2.6% 2.6% 0.0 pts −262 sh 0%
Reduced OCULIS HOLDING AG (OCS) 1.8% 1.8% +0.1 pts −158 sh 0%
Reduced VERASTEM INC (VSTM) 5.9% 3.2% −2.7 pts −530 sh 0%

Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled

Top 10 positions — 71.0% of the equity book

Changes in the top 10 this quarter: CMPS entered · IVA entered · VSTM left · GPCR left

# Security Weight before Weight now
1 TERNS PHARMACEUTICALS INC (TERN) 13.1% 14.8%
2 PROTAGONIST THERAPEUTICS INC (PTGX) 11.8% 11.2%
3 SHATTUCK LABS INC (STTK) 6.7% 9.4%
4 VOR BIOPHARMA INC (VOR) 7.7% 8.3%
5 COMPASS PATHWAYS PLC (CMPS) 3.0% 5.2% Entered the top 10
6 RHYTHM PHARMACEUTICALS INC (RYTM) 4.2% 5.1%
7 XENON PHARMACEUTICALS INC (XENE) 4.8% 4.9%
8 PALVELLA THERAPEUTICS INC NE (PVLA) 5.1% 4.8%
9 ZENAS BIOPHARMA INC (ZBIO) 6.9% 3.9%
10 INVENTIVA SA (IVA) 3.5% 3.4% Entered the top 10
— VERASTEM INC (VSTM) 5.9% 3.2% Left the top 10
— STRUCTURE THERAPEUTICS INC (GPCR) 3.9% 3.0% Left the top 10

Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).